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ABSTRACT
Malignant pleural mesothelioma (MPM) is a very aggressive form of cancer with 
a poor diagnosis and prognosis. The first line treatment for MPM is a combination of 
cisplatin and Pemetrexed, which displayed limited efficacy and severe side effects. 
The naturally occurring compound phenethyl isothiocyanate (PEITC) previously 
showed interesting anti-tumor properties on several cancer cell lines. We thus aim 
at evaluating PEITC used alone or in combination with cisplatin in order to improve 
MPM treatment. 
Nine MPM cell lines and primary mesothelial cells (PMC), co-cultured or not with 
M2 macrophages present in MPM microenvironment, were used to assess PEITC and 
cisplatin anti-tumor properties. Compounds were used alone or in combination. 
Both PEITC and cisplatin were cytotoxic on MPM cells in a dose dependent 
manner. We herein showed that PEITC-induced cytotoxicity was due to the generation 
of reactive oxygen species. Moreover, we showed that cisplatin-PEITC combination 
allowed the potentialization of both compounds’ cytotoxic effects and prevented 
the emergence of resistant MPM cells. Interestingly, PMC were not sensitive to 
the combination. Finally, we showed that M2 macrophages did not alter the anti-
tumor properties of the combination. Cisplatin-PEITC combination thus represents a 
promising strategy to induce a selective toxicity towards malignant cells.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is an 
aggressive neoplasm affecting the mesothelial surfaces 
of pleural and peritoneal cavities [1] mainly arising from 
a chronic exposure to and inhalation of asbestos [2]. Its 
aggressiveness and critical health care matter mainly 
arise from its late diagnosis and poor prognosis (less 
than a year after diagnosis). The first line treatment for 
MPM lies in the combination of cisplatin with an anti-
metabolite: the Pemetrexed (Alimta). There are several 
clinical trials relating this combination to treat MPM [3-
4], that lead to better response compared to cisplatin alone 
[5]. However, this improvement remains modest and only 
half of the patients respond to the combination [6]. It is 
thus necessary to find new therapeutic approaches to treat 
MPM.
It has now been described for many years that 
frequent consumption of cruciferous vegetables reduces 
the incidence of cancer [7]. The active compounds 
primarily responsible for those cancer chemopreventive 
properties were described to be the glucosinolates [8-9], 
which are substituted B-thioglucoside N-hydroxysulfates 
synthesized by the plant from 8 amino acids. However, the 
inhibition of carcinogenesis seems to rather be attributable 
to some of their breakdown products: the isothiocyanates 
(ITCs) [10]. 
ITCs anticarcinogenic properties mechanisms 
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of action are still under investigation but it is now 
established that it stems from their ability to disrupt 
multiple carcinogenic process step. They were shown to 
reduce genetic damage, inhibit genetically damaged cell 
proliferation thanks to the induction of apoptosis and cell 
cycle arrest, but were also involved in malignant cells 
differentiation [11-12]. These anti-tumor effects may be 
due to the generation of Reactive Oxygen Species (ROS) 
that was previously reported to be one of Benzyl ITC 
(BITC) mechanisms of action [13-14]. 
In animal models, more than 20 ITCs were shown 
to inhibit carcinogenesis induced by several chemical 
carcinogens [11,15]. In human, it has been reported that 
those vegetables are good protective agents against several 
kinds of cancer: colorectal [16], lung [17] and possibly 
prostate cancers [18]. Among all ITCs, it was shown in 
vivo that Phenethyl Isothiocyanate (PEITC) was able to 
reach the highest plasma concentration after oral ingestion 
[19], at a micromolar dose range. Interestingly, micromolar 
doses of PEITC applied to animal and cell culture 
models were shown to prevent cancer, through several 
mechanisms that still need to be further investigated 
[10,20]. We thus wondered whether combining cisplatin 
with PEITC could be of potential therapeutic benefits for 
patients suffering from MPM, and if it could lead to less 
side effects and more specificity on cancer cells.
For these purposes, we focused on the anti-tumor 
properties of PEITC alone or in combination with cisplatin 
on a large collect of MPM cell lines freshly established 
from patients’ pleural effusions in our laboratory. We 
demonstrated for the first time that PEITC is cytotoxic 
for MPM cells through ROS production. Moreover, 
cisplatin-PEITC combination allowed potentialization 
of both compounds’ cytotoxic effects and prevented the 
emergence of resistant MPM cells. Interestingly, healthy 
primary mesothelial cells (PMC) were not sensitive to the 
combination. Finally, the presence of M2 macrophages did 
not change the anti-tumor properties of the combination. 
Our results suggest that cisplatin-PEITC combination 
could be of great interest for MPM treatment.
RESULTS
PEITC increases MPM cells cytotoxicity through 
ROS production
PEITC was previously demonstrated to exert 
cytotoxic effects on tumor cells by increasing ROS 
intracellular level [23]. In order to evaluate the antitumor 
properties of PEITC, cell cytotoxic assays were conducted 
on three MPM cell lines: Meso4, Meso11, Meso152, 
treated with increasing doses of PEITC alone or in 
combination with NAC, a powerful antioxidant amino 
acid. NAC was used to highlight the implication of ROS 
in PEITC-induced cell death. Indeed, ROS production 
would be inhibited by NAC treatment. Cell cytotoxicity 
with PEITC treatment was increased in a dose-dependent 
manner, and PEITC had a similar potency on all cell 
lines. The IC50 value was 7.4 ± 0.2µM for MPM cell lines 
(Figure 1A). PEITC-induced cytotoxicity was inhibited by 
a co-treatment with NAC, suggesting the implication of 
ROS production in this effect.
Then, PEITC-induced ROS in MPM cells was 
investigated to determine whether it could be part of the 
mechanisms involved in cytotoxic effects on cancer cells. 
Hydrogen peroxide (H2O2) has very strong oxidizing 
properties and was used as a positive control for ROS 
production. Cell death induction was measured with 
Annexin-V cells staining (Figure 1B). ROS production 
was assessed by flow cytometry thanks to cells pre-
incubation with the CM-H2DCFA specific fluorescent 
probe (Figure 1C).We observed, in a dose-dependent 
manner, that PEITC-induced ROS generation was 
consistent with PEITC-induced cell death in all tested cell 
lines (Figure 1B and C). In the presence of NAC, ROS 
generation and cell cytotoxicity were decreased, strongly 
suggesting the causative link between ROS generation and 
PEITC-induced cell death. As a control, H2O2 was shown 
to induce apoptosis and ROS production in MPM cells. 
 Cisplatin increases MPM cells cytotoxicity partly 
in a ROS dependent manner
Several studies demonstrated the implication of an 
oxidative stress generation in cisplatin cytotoxic effects 
[24]. Thus, cisplatin dose-response experiments were 
carried out on the same three MPM cell lines previously 
tested. All cell lines were sensitive to cisplatin in a dose 
dependent manner. The IC50 value was 1.8 ± 0.21mg/L 
for MPM cell lines (Figure 2A). Treatment with NAC 
decreased cisplatin-induced cell cytotoxicity on all tested 
cell lines, arising from the possible induction of ROS by 
cisplatin.
To confirm the implication of an oxidative stress in 
the cytotoxic effect of cisplatin, we similarly investigated 
whether cisplatin induced-cell death is related to a ROS 
production and inhibited by NAC (Figures 2B and C). 
However, cisplatin-induced cell death did not entirely 
correlate with a production of ROS. Indeed, although 
almost 40% of cells died from a treatment with the highest 
concentration of cisplatin (25mg/L) (Figure 2B), yet no 
production of ROS was detected (Figure 2C). Cells co-
treated with cisplatin (25mg/L) and NAC seemed to be 
more resistant to death than those untreated with NAC: 
almost 40% of cells died with cisplatin alone while 
about 23% of MPM cells died with the combination. 
As a control, H2O2 induced ROS production and MPM 
cell death. H2O2 effects were totally inhibited by a co-
treatment with NAC, demonstrating its efficacy to block 
ROS-induced cell death.
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Figure 1: Effect of PEITC on MPM cell lines. Three cell lines of MPM (Meso4, 11 and 152) were treated with increasing doses of 
PEITC alone or combined to NAC (5mM) for 72h. Cell viability was determined using Uptiblue reagent. Values represent the mean ± SEM 
of three independent measurements. B and C, MPM cell lines were treated with three doses of PEITC alone or combined to NAC (5mM) for 
24h. Cell death (B) was measured by flow cytometry, after Annexin-V-APC cell staining. Cell death induction is expressed in percentage of 
annexin-V-APC labeled cells. ROS detection (C) was performed with flow cytometry thanks to a specific molecular probe CM-H2DCFA. 
Fluorescence values are expressed in Relative Mean Fluorescence Intensity (RMFI). Values represent the mean ± SEM of three independent 
measurements on three distinct cell lines.
Figure 2: Effect of cisplatin on MPM cell lines. Three cell lines of MPM were treated with increasing doses of cisplatin alone 
or combined to NAC (5mM) for 72h. Cell viability was determined using Uptiblue reagent. Values represent the mean ± SEM of three 
independent measurements. B and C, MPM cell lines were treated with three doses of cisplatin alone or combined to NAC (5mM) for 24h. 
Cell death (B) was measured by flow cytometry, after Annexin-V-APC cell staining. Cell death induction is expressed in percentage of 
annexin-V-APC labeled cells. ROS detection (C) was performed with flow cytometry thanks to a specific molecular probe CM-H2DCFA. 
Fluorescence values are expressed in RMFI. Values represent the mean ± SEM of three independent measurements on three distinct cell 
lines.
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Cisplatin-PEITC combination potentiates their 
cytotoxic effect through enhanced DNA damage
Studies carried out on other cancer types such as 
non-small cell lung cancer, ovarian, testicular or cervical 
cancer demonstrated the implication of DNA damage in 
cisplatin and PEITC cytotoxic effects [25-26]. We herein 
evaluated on MPM cells the combination cisplatin-PEITC 
on DNA damage by looking at the phosphorylation on 
serine 139 of histone H2A.X (P-H2A.X), a specific marker 
for DNA damage [27] (Figure 3 and additional figure 
S2). No DNA damage was triggered by PEITC alone, 
according to P-H2A.X staining, in any cell line. While no 
DNA damage was observed in MPM cells after cisplatin 
treatment alone, combination of cisplatin with PEITC 
strongly enhanced P-H2A.X signal. This result suggests 
a potentialization of both compounds’ effect on DNA 
damage, indeed triggering more lesions than compounds 
used alone. Combination of cisplatin with PEITC would 
thus potentiate their apoptotic effect through DNA 
damage.
Cisplatin-PEITC combination enhances MPM 
cytotoxicity and prevents the generation of 
resistant cells
Cisplatin and PEITC cytotoxic effects after 72h of 
treatment were assessed using Uptiblue viability assay. 
Both compounds were used alone or in combination on 
MPM cells seeded in 96 well plates. Three concentrations 
of PEITC were evaluated, and cisplatin concentration 
(0.8mg/L) was used to trigger approximately 40% 
of cell death (Figure 4A). MPM cell lines died in a 
dose dependant manner for all PEITC concentrations. 
Cell death was significantly enhanced with combined 
compounds after 72h at all PEITC concentrations. It was 
the most obvious with the 6µM PEITC concentration, as 
there was almost 80% of cell death with the combination, 
when each compound alone only induced about 40% 
of cell death. Cisplatin-PEITC combination cytotoxic 
effect on MPM cells was also assessed over 10 days 
using a clonogenic assay (Figure 4B). Cells were seeded 
at a small density and treated for 10 days with PEITC 
and cisplatin alone or in combination. Previous dose-
response experiments allowed us to choose an appropriate 
concentration for each compound that would not trigger 
more than 35% of cell death, in order to be able to 
observe a possible potentialization of both compounds 
effect with the combined treatment. After 10 days of 
treatment, cells were fixed and stained with crystal violet 
to obtain images and quantification of cell proliferation. 
The results shown in the figure 4B are representative of 
three independent experiments conducted on two MPM 
cell lines. Results obtained in the six experiments are 
provided individually as supplementary data (Figure S3). 
For both cell lines, PEITC and cisplatin increase cell death 
compared to untreated cells. PEITC is more potent than 
Figure 3: Cisplatin-PEITC combination induces the DNA recruitment of the histone H2A.X phosphorylated form in 
MPM cells. Cells were treated with cisplatin (0.8mg/l) and PEITC (4µM) alone or in combination for 24h prior to PAF 4% fixation and 
immunofluorescence staining for P-H2AX. Representative images of MPM cells (Meso152) stained for P-H2A.X (pink), stained with 
DAPI (blue) for nuclei labeling and merge pictures. 
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cisplatin while the combination of both compounds leads 
to a clear potentialization of PEITC and cisplatin effects. 
This result suggests that the combination of cisplatin 
with PEITC potentiates their cytotoxic effect on MPM 
cells. Furthermore, the effect of PEITC and cisplatin on 
MPM cells viability over time was assessed over nine 
days in order to establish a kinetic of both compounds 
used alone or in combination (Figure 4C). Viability 
was measured after 3, 6 and 9 days of treatment and 
showed that cisplatin-PEITC combination significantly 
potentiated both compounds’ cytotoxic effects. After 3 
days of combined treatment, there was about 34% viable 
cells while compounds alone led to approximately 60% 
of viable cells. At day 9, there were about 28% viable 
cells with cisplatin alone and 47% with PEITC. However, 
cisplatin-PEITC combination led to less than 5% viable 
cells after 9 days of treatment, thus suggesting a strong 
synergy when both compounds were combined. Indeed, 
the combination not only led to a significant increase of 
cell death but more importantly prevented the emergence 
of chemoresistance, making of this strategy a good 
candidate to treat reluctant cancer such as MPM.
Cisplatin and PEITC combination is well 
tolerated by primary mesothelial cells
Aiming at evaluating the toxicity of cisplatin-
PEITC combination on healthy cells, PMC were treated 
with cisplatin and PEITC alone or in combination for 
Figure 4: Effect of PEITC and cisplatin alone or in combination on MPM cells. A, MPM cell viability assays were performed 
after 72h of cisplatin and/or PEITC treatments using Uptiblue cell counting reagent. Three concentrations of PEITC were used (2, 4 and 
6µM), alone or in combination with cisplatin at 0.8mg/l. Values represent the mean ± SEM of three independent measurements on three 
distinct cell lines. B, MPM cells (Meso 4 and Meso 152) were treated with cisplatin (0.05mg/l) and PEITC (2µM) alone or in combination 
for 10 days. At day 10, cells were fixed, stained with Crystal Violet and coloration quantified. Histograms represent the mean ± SEM 
of three independent experiments performed on two MPM cell lines. C, treatments with cisplatin (0.8mg/l) and/or PEITC (6µM) were 
performed every three days to assess cell viability over 9 days. Viability was measured at day 3, 6 and 9 using Uptiblue cell counting 
reagent. Compounds concentration was adapted to 96 well plate and cell number, in order to reach at most 40% cell death after 72h of 
treatment. Values represent the mean ± SEM of three independent measurements on three distinct MPM cell lines. * p<0.05.
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72h. Microscopy pictures (Figure 5A) and viability assay 
(Figure 5B) showed that PMC were not affected by either 
compounds alone or combined. Moreover, a comparison 
between MPM and PMC clearly illustrates the safety of 
our strategy for healthy cells while inducing almost 100% 
MPM cell death (Figure 5C). This experiment suggests 
that the combination could be injected in pleural cavities 
with no side effect on cells of healthy pleura.
Additional MPM cell lines are also sensitive to 
Cisplatin-PEITC combination
The absence of cisplatin-PEITC toxicity on PMC 
led us to compare the sensitivity of six additional MPM 
cell lines from our biocollection (Figure 6). Half of MPM 
tested cell lines (Meso13, Meso34 and Meso56) displayed 
a strong resistance phenotype to cisplatin or PEITC after 
the second treatment repetition. Cytotoxic effect and cell 
death were significantly enhanced by combining both 
compounds, but their kinetics were variable according to 
each cell line. Indeed, combination best efficiency was 
observed at day 3 for Meso47, 56 and 76 and at day 6 for 
Meso13, 34 and 96. However, for all cell lines, combining 
both compounds significantly improved their cytotoxic 
effects, compared to compounds alone, indeed leading to 
less than 10% of viable cells after 9 days of treatment. 
Cisplatin-PEITC combination is toxic on MPM 
cells in the presence of M2 macrophages while 
remaining safe for primary mesothelial cells
The tumor microenvironment is much different 
than the physiological one, and it is now well known 
that a number of factors can play an important role in 
the development of the tumor and in the efficiency of 
the treatment. As an example, M2 macrophages are cells 
present in the microenvironment of many cancer types, 
including mesothelioma, and have been described as 
enhancers of tumor cell proliferation [28]. Moreover, 
macrophages are cells that constitutively produce ROS 
[29], they could thus be envisioned as potentially harmful 
if combined to a compound also generating ROS. We 
thus evaluated the cytotoxic effect of cisplatin-PEITC 
combination on MPM and PMC in the presence of 
macrophages (Figure 7). A differentiation experiment 
was carried out from monocytes in order to obtain M2 
macrophages that were phenotyped by Flow Cytometry 
prior to their seeding at several concentrations in 96 well 
plates (Figure S4), in co-culture with MPM or PMC. The 
following day, cells were treated with cisplatin 0.8mg/l in 
combination with PEITC at 4µM or 6 µM for 72h. The 
results show that the combination was toxic on MPM cells 
no matter which concentration of PEITC considered, in 
Figure 5: Effect of PEITC and cisplatin alone or in combination on primary mesothelial cells. PMC were treated with 
cisplatin (0.8mg/l) and/or PEITC (6µM) for 72h. A, Microscopy pictures were taken, and B, viability assays were performed. C, Comparison 
of cisplatin-PEITC combination on MPM and PMC. Graphics represent the mean ± SEM of triplicates. ** p<0.01, *** p<0.001.
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the presence or not of M2 macrophages. As previously 
observed, the combination was safe on PMC for both 
concentrations of PEITC. Even though the presence of 
macrophages seemed to sensitize PMC to the combination 
with the highest concentration of PEITC, the combination 
of cisplatin with 4µM of PEITC remained safe whereas 
being highly toxic on MPM cells. This experiment thus 
allowed us to prove that the combination cisplatin-PEITC 
at a dose cytotoxic for MPM cells still remains non toxic 
on PMC in the presence of M2 macrophages.
DISCUSSION
Treatment of MPM represents a major public health 
challenge given its aggressiveness, poor prognosis after 
diagnosis and more importantly its lack of effective 
curative therapies. The first line treatment consists in 
a combination of cisplatin with the Pemetrexed anti-
metabolite [3-4]. Although this combination showed 
greater results than drugs used alone, the benefit for 
patients remains insufficient. The investigation of new 
therapeutic strategies to approach this thoracic malignancy 
thus became a necessity. 
ITCs, arising from the hydrolysis of glucosinolates 
contained in cruciferous vegetables, are well known for 
their anti-carcinogenic properties [10]. Growth of several 
kinds of cancer cells was shown to be inhibited by ITCs: 
leukemia [30-31], prostate cancer [32], breast cancer [33-
34], colorectal cancer [35] etc. PEITC, a member of ITCs 
family, was described as an important anti-carcinogenic 
compound in humans [10,20]. Using MPM cell lines 
established in our laboratory from patients’ pleural fluids, 
we demonstrated for the first time that these cells were 
sensitive to this compound. Furthermore, we showed that 
PEITC-induced MPM cell death by apoptosis was fully 
dependent on ROS production.
Figure 6: Effect of PEITC and cisplatin alone or in combination on MPM cells viability over time. MPM cells treatment 
with cisplatin (0.8mg/l) and/or PEITC (6µM) were performed every three days to assess cell viability over 9 days. Viability was measured 
at day 3, 6 and 9 using Uptiblue cell counting reagent. Values represent the mean ± SEM of triplicates. * p<0.05, ** p<0.01, *** p<0.001.
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However, the benefit of MPM first line treatment is 
insufficient and needs to be improved. A previous study 
demonstrated an interesting potentialization of cisplatin 
effect when combined to PEITC in a model of lung cancer 
[36]. This study suggested that PEITC could be a good 
candidate to improve the effect of cisplatin on MPM cells. 
We first characterized the effect of cisplatin on 
our MPM cell lines. We observed a dose dependent 
toxicity of cisplatin through apoptosis induction partly 
dependent on an oxidative stress, as demonstrated by 
the use of NAC. We then demonstrated that PEITC-
induced cytotoxic effects were entirely mediated through 
oxidative stress generation in cells, while there was more 
than this mechanism involved in cisplatin-induced cell 
death mechanisms of action. Although a couple of studies 
recently investigated the impact of cisplatin-PEITC 
combination on other cancer types [37-38], our work 
focuses for the first time on MPM, and brings new insights 
for a better approach of this incurable disease. Healthy 
and malignant mesothelioma models had previously 
been investigated using similar strategies acting on the 
induction of an oxidative stress alone or in combination 
with cisplatin, confirming the relevance of these strategies 
[39-40]. However, we here in showed for the first time that 
cisplatin-PEITC combination significantly enhanced MPM 
cell death, potentiated DNA damage and more importantly 
is safe for healthy cells and prevents the emergence of 
resistant cells.
Cisplatin-PEITC combination showed a decrease 
of cell viability after 72h of treatment. Moreover, a 
clonogenic assay carried out over 10 days on MPM cells 
confirmed that the combination led to a potentialization of 
both compounds’ cytotoxic effect. Although cisplatin and 
PEITC showed interesting anti-tumor activity after 72h 
when used alone, repeated treatments led to the apparition 
of resistant cells characterized by a loss of compounds’ 
efficacy to increase cell cytotoxicity over time. Indeed, 
we observed, in more than half of MPM tested cell lines, 
a decrease of sensitivity or a resistance towards each 
molecule. This could explain the poor therapeutic benefit 
of cisplatin on MPM patients and could also suggest 
that PEITC used alone would have limited efficacy for 
its clinical use. The mechanisms of action of these two 
molecules were already described and mainly result 
in the formation of DNA damage [25-26]. Our results 
confirmed the adaptive capacities of tumor cells to this 
class of chemotherapeutic-induced lesions. However, 
DNA damage induced by cisplatin or PEITC is of different 
nature thus implying the involvement of distinct pathways 
of the DNA damage response (DDR) for cells to bypass 
those lesions. MPM patients sensitivity to cisplatin was 
previously correlated to mRNA expression of the excision 
repair cross-complementation group 1 (ERCC1) involved 
in the nucleotide excision repair (NER) pathway [41]. 
ROS production in cells acts by different mechanisms to 
damage DNA bases, but mainly affects guanine that gets 
Figure 7: Effect of cisplatin-PEITC combination on MPM and primary mesothelial cells co-cultured with M2 
macrophages. MPM and PMC were co-cultured with M2 macrophages at two densities: 100 M2/well or 10 M2/well and treated with 
cisplatin at 0.8 mg/l in combination with PEITC at 4µM or 6µM for 72h. Viability was measured using Uptiblue cell counting reagent. 
Values are expressed in percentage of control and represent the mean ± SEM of experiments conducted on three MPM cell lines, or in 
duplicates for PMC. * p<0.05, ** p<0.01.
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transformed into 8-oxo-2’deoxyguanosine (8-oxoG) [42]. 
The main DNA repair mechanism involved to remove 
ROS-induced DNA lesions is the base excision repair 
(BER) pathway [42]. Therefore, we hypothesized that 
by combining cisplatin with PEITC, both BER and NER 
pathways would be activated. The possibility to raise 
resistant cells would thus be limited due to the difficulty 
for a cell to set up two pathways of the DDR at the same 
time. Our results demonstrated that all tested cell lines 
were sensitive to cisplatin-PEITC combination, reaching 
less than 5% of viable cells after three repetitions of 
treatment. We thus showed a correlation between cisplatin-
PEITC cytotoxicity and DNA damage potentialization 
triggered by the combination, as illustrated by the 
recruitment of the phosphorylated histone H2A.X to the 
DNA [27]. These last results therefore demonstrated that 
the DDR machineries were overwhelmed, preventing the 
generation of resistant cells. 
Interestingly, cisplatin-PEITC combination induced 
absolutely no toxicity on PMC while the same treatment 
induced MPM cell death. By performing repetitive 
treatments over nine days, we also demonstrated that 
the combination prevented the emergence of resistant 
tumor cells. Indeed, we confirmed that the combination 
was efficient on nine MPM cell lines while more than 
half of them became resistant to drugs used alone. These 
results suggest that cisplatin-PEITC combination could 
be an interesting strategy to treat MPM using a local 
administration regarding its lack of toxicity on PMC. The 
higher sensitivity of MPM cells to the combined treatment 
compared to PMC probably results from the capacity 
of PMC to support mild and severe oxidative stress, 
thanks to gluthatione redox cycle and catalase-mediated 
protection [43]. Usually, these anti-oxydant pathways are 
altered in malignant cells and associated with an increased 
metabolic activity. These changes lead to a higher level 
of ROS in malignant cells compared to healthy cells, 
which contribute to promote oncogenic properties such as 
generation of resistant cells to conventional therapies but 
also to sensitize cells to strong oxidative stress [42]. This 
combination already demonstrated its efficacy on breast 
cancer [37] and leukemia cells [44] while displaying no 
toxicity on their healthy counterpart, suggesting a good 
tolerability of healthy cells towards cisplatin-PEITC 
combination. 
The tumoral microenvironment plays an important 
role in the development of the tumor and several actors are 
involved [45]. Among all cells present in the environment 
of the tumor, macrophages are of significant importance 
and have been described as enhancers of tumor cell 
proliferation [28]. Moreover, macrophages are cells that 
constitutively produce ROS [29], which could be of harm 
if added to a compound also generating ROS. We thus 
investigated the effect of cisplatin-PEITC combination 
on MPM and PMC in co-culture with macrophages. 
We showed that cisplatin-PEITC was toxic on MPM 
cells for both concentrations of PEITC. The presence of 
macrophages did not modify the sensitivity of MPM cells 
to the combination. Moreover, although the strongest 
concentration of PEITC (6µM) combined to cisplatin 
led to a higher sensitivity of PMC to the combination, 
we showed that cisplatin combined to PEITC at 4µM 
was toxic on MPM cells while remaining safe for PMC. 
The highest sensitivity of PMC to cisplatin combined to 
the highest concentration of PEITC thus confirms the 
importance of the microenvironment in the toxicity of 
the treatments. However, for a dose of cisplatin-PEITC 
highly toxic on MPM cells, we demonstrated here that this 
combination remains safe on PMC. 
Therefore, a local administration of cisplatin-
PEITC combination in pleural cavity could be a promising 
strategy to induce selective toxicity towards malignant 
cells. Altogether, cisplatin-PEITC combination would 
enhance cancer cell death compared to compounds used 
alone and prevent the emergence of cell resistance, while 
remaining safe for PMC. 
CONCLUSION
The combination of cisplatin with the natural 
compound PEITC induces a strong MPM cell death, while 
remaining safe for PMC, with limited emergence of cell 
resistance compared to drugs used alone. Therefore, this 




The nine mesothelioma cell lines: Meso4, 
Meso11, Meso13, Meso34, Meso47, Meso56, Meso76, 
Meso96 and Meso152 were established from pleural 
fluids of patients [21]. These cells were characterized 
for the mRNA expression of the usual MPM markers 
by immunohistochemistry (Figure S1) and belong to a 
validated biocollection (Ministère de l’Enseignement 
Supérieur et de la Recherche n° DC-2011-1399 and 
Commission Nationale de l’Informatique et des Libertés 
(CNIL) n°: 1657097). All cell lines were maintained 
in RPMI medium (Invitrogen) supplemented with 
2mM L-glutamine, 100IU/ml penicillin, 0.1mg/ml 
Streptomycin and 10% heat-inactivated fetal calf serum 
(Eurobio) and cultured at 37°C in a 5% CO2 atmosphere. 
Primary mesothelial cells (PMC) from peritoneal origin 
were purchased from Tebu-bio biosciences and cultured 
according to the manufacturer’s recommendations.
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Drugs
PEITC, N-acetyl-cystein (NAC) and cisplatin were 
purchased from Sigma-Aldrich. 
Determination of cell viability
Cell viability was monitored using Uptiblue reagent 
(Interchim) as previously described [22]. Cells were 
seeded in 96-well plates at a density of 5x103cells/well for 
MPM cells in culture medium for 24h. Then compounds 
were added for an additional 72h and Uptiblue reagent 
(5%, v/v) was then added to the culture medium for 2h 
at 37°C. Fluorescence was measured at 605nm after a 
green epi illumination excitation using a ChemiDoc™ MP 
imaging system (Biorad). Quantification was performed 
using ImageJ 1.41o software. For kinetic experiments, 
culture medium containing Uptiblue was replaced by 
medium with or without drug for 72h and the procedure 
for cell viability measurement was repeated twice. Results 
were expressed as percentage of untreated cells.
 Detection of Reactive oxygen species
Cells were seeded at a density of 1x106cells/well in 
12 well plates. 24h after seeding, cells were washed once 
with PBS and incubated for 30min at 37°C with the CM-
H2DCFA probe (Life Technologies), resuspended in PBS 
at a final concentration of 5µM, washed once with PBS and 
treated with Cisplatin or PEITC alone or in combination. 
24h after treatment, cells and their supernatant were 
harvested and analyzed by flow cytometry (FACSCalibur; 
Becton Dickinson). Ten thousand events were collected 
and analyzed with the FACS Flowjo Software (Tree Star 
Inc). 
Detection of apoptosis
Cells were seeded at a density of 1x106cells/well in 
6-well plates and treated with indicated concentrations. 
After 24h, floating and adherent cells were combined, 
labeled using Annexin V-allophycocyanin (APC) (Becton 
Dickinson) following the manufacturer’s instructions, 
and analyzed by flow cytometry (FACSCalibur; Becton 
Dickinson). Ten thousand events were collected and 
analyzed with the FACS Flowjo Software (Tree Star Inc). 
Clonogenic assay
Two MPM cell lines were used to assess their effect 
on MPM cells proliferation: Meso4 and Meso152. This 
assay requires cells that grow in colonies, which was not 
the case of the third cell line used over this study for the 
other experiments (Meso11). Cells were seeded in 6-well 
plates at a density of 500 cells/well for Meso4 and 1000 
cells/well for Meso152, according to each cell line rate 
of proliferation. 24h after seeding, cells were treated with 
PEITC alone at 2µM or in combination with cisplatin at 
0.05mg/l for 10 days. At day 3, half of the medium was 
replaced with fresh medium, and at day 5, the totality of 
the medium was replaced by fresh medium until the end 
of the experiment. At day 10, cells were fixed with 4% 
paraformaldehyde in PBS and stained with 0.05% crystal 
violet in ethanol 70%. Cells were then imaged using a 
ChemiDoc™ MP imaging system (Biorad). Quantification 
was performed using ImageJ 1.41o software.
Co-culture assay
MPM and PMC were co-cultured with M2 
macrophages and treated with cisplatin and PEITC 
alone or in combination for 72h. Three MPM cell lines 
were used: Meso4, 11 and 152, seeded in a 96 well plate 
at a density of 5.103 cells/well. According to cell rate 
proliferation, primary mesothelial cells were seeded at a 
density of 2.104 cells/well in order to create a cell layer 
similar to the physiological conditions. M2 macrophages 
were obtained from monocytes that were differentiated 
with a treatment with M-CSF (50ng/ml). As a control, 
a fraction of monocytes was also treated with GM-CSF 
(20ng/ml) to obtain M1 macrophages. After 5 days, both 
M-CSF and GM-CSF-treated monocytes were harvested 
and characterized by flow cytometry using CD14-FITC 
and CD163-APC staining. M2 macrophages were seeded 
in co-culture with MPM or PMC at two concentrations: 
100 and 10 macrophages per well. 24h after seeding, cells 
were treated with cisplatin at 0.8mg/l in combination with 
PEITC at 4µM or 6µM for 72h. Cell viability was then 
measured using Uptiblue counting reagent as described 
above. Fluorescence was measured at 605nm after a green 
epi illumination excitation using a ChemiDoc™ MP 
imaging system (Biorad). Quantification was performed 
using ImageJ 1.41o software.
Microscopic experiments
Cells were seeded in culture medium on glass 
coverslips at a density of 5x104cells/well in 12 well plates. 
24h later, drugs alone or in combination were added for 
additional 24h. Cells were washed twice with PBS and 
fixed with 4% paraformaldehyde in PBS, 15min at room 
temperature. Cells were permeabilized with 0.05% Triton 
X-100 (Merck) /0.05% Tween-20 (Sigma-Aldrich) in 
PBS (5min) and incubated with anti-γH2A.X (phospho 
S139) antibody at 1µg/ml (Abcam) in PBS/1% BSA for 
1h. Cells were washed twice with PBS and incubated 
with a DyLighttm 633 conjugated secondary antibody 
(Thermo Scientific) for 1h. After an additional PBS wash, 
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cell nuclei were stained with 1µg/ml Hoechst (Sigma-
Aldrich) (5min). Coverslips were mounted in ProLong® 
Gold (Molecular Probes) and fluorescence was visualized 
using the Axiovert200M microscopy system (Zeiss, Le 
Pecq, France) with ApoTome module (X63 and numerial 
aperture 1.4).
Statistical analysis
Statistical analyses were performed using GraphPad 
prism, (Prism 5, Windows). Data are expressed as the 
means ± S.E.M. of at least three experiments. Statistical 
comparisons were made using the nonparametric Mann-
Whitney test.
ACKNOWLEDGEMENTS
This work was supported by INSERM, CNRS, the 
Ligue National Contre la Cancer for ID grant, the Ligue 
inter-regionale Contre le Cancer: committees of Morbihan, 
Sarthe, Vendée, Loire-Atlantique and Poitou-Charentes, 
ARSMESO44. The authors thank MicroPICell and 
Cytocell core facilities for the microscopic and the flow 
cytometry experiments, respectively.
Competing interests
The authors declare that they have no competing 
interests.
REFERENCES
1. Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted 
therapies for unresectable malignant mesothelioma. Lung 
Cancer. 2011; 73: 256-263.
2. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural 
mesothelioma and asbestos exposure in the North Western 
Cape Province. Br J Ind Med. 1960; 17: 260-271.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham 
C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, 
Manegold C, Niyikiza C, Paoletti P. Phase III study of 
pemetrexed in combination with cisplatin versus cisplatin 
alone in patients with malignant pleural mesothelioma. J 
Clin Oncol. 2003; 21: 2636-2644.
4. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren 
RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, 
Debruyne C, Giaccone G. Randomized phase III study 
of cisplatin with or without raltitrexed in patients with 
malignant pleural mesothelioma: an intergroup study of 
the European Organisation for Research and Treatment 
of Cancer Lung Cancer Group and the National Cancer 
Institute of Canada. J Clin Oncol. 2005; 23: 6881-6889.
5. Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van 
Meerbeeck J. Advances in the systemic therapy of 
malignant pleural mesothelioma. Nat Clin Pract Oncol. 
2008; 5: 136-147.
6. Remon J, Lianes P, Martinez S, Velasco M, Querol R, 
Zanui M. Malignant mesothelioma: New insights into a rare 
disease. Cancer Treat Rev. 2012.
7. Glade MJ. Food, nutrition, and the prevention of cancer: a 
global perspective. American Institute for Cancer Research/
World Cancer Research Fund, American Institute for 
Cancer Research, 1997. Nutrition. 1999; 15: 523-526.
8. Fenwick GR, Heaney RK, Mullin WJ. Glucosinolates and 
their breakdown products in food and food plants. Crit Rev 
Food Sci Nutr. 1983; 18: 123-201.
9. Johnson IT. Glucosinolates: bioavailability and importance 
to health. Int J Vitam Nutr Res. 2002; 72: 26-31.
10. Hayes JD, Kelleher MO, Eggleston IM. The cancer 
chemopreventive actions of phytochemicals derived from 
glucosinolates. Eur J Nutr. 2008; 47 Suppl 2: 73-88.
11. Zhang Y, Talalay P. Anticarcinogenic activities of organic 
isothiocyanates: chemistry and mechanisms. Cancer Res. 
1994; 54: 1976s-1981s.
12. Conaway CC, Yang YM, Chung FL. Isothiocyanates as 
cancer chemopreventive agents: their biological activities 
and metabolism in rodents and humans. Curr Drug Metab. 
2002; 3: 233-255.
13. Sahu RP, Zhang R, Batra S, Shi Y, Srivastava SK. Benzyl 
isothiocyanate-mediated generation of reactive oxygen 
species causes cell cycle arrest and induces apoptosis via 
activation of MAPK in human pancreatic cancer cells. 
Carcinogenesis. 2009; 30: 1744-1753.
14. Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate 
targets mitochondrial respiratory chain to trigger reactive 
oxygen species-dependent apoptosis in human breast cancer 
cells. J Biol Chem. 2008; 283: 30151-30163.
15. Hecht SS. Chemoprevention by isothiocyanates. J Cell 
Biochem Suppl. 1995; 22: 195-209.
16. van Poppel G, Verhoeven DT, Verhagen H, Goldbohm RA. 
Brassica vegetables and cancer prevention. Epidemiology 
and mechanisms. Adv Exp Med Biol. 1999; 472: 159-168.
17. London SJ, Yuan JM, Chung FL, Gao YT, Coetzee 
GA, Ross RK, Yu MC. Isothiocyanates, glutathione 
S-transferase M1 and T1 polymorphisms, and lung-cancer 
risk: a prospective study of men in Shanghai, China. Lancet. 
2000; 356: 724-729.
18. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett 
WC. A prospective study of cruciferous vegetables and 
prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003; 
12: 1403-1409.
19. Ji Y, Kuo Y, Morris ME. Pharmacokinetics of dietary 
phenethyl isothiocyanate in rats. Pharm Res. 2005; 22: 
1658-1666.
20. Keum YS, Jeong WS, Kong AN. Chemopreventive 
functions of isothiocyanates. Drug News Perspect. 2005; 
18: 445-451.
21. Gueugnon F, Leclercq S, Blanquart C, Sagan C, Cellerin 
Oncotarget11652www.impactjournals.com/oncotarget
L, Padieu M, Perigaud C, Scherpereel A, Gregoire M. 
Identification of novel markers for the diagnosis of 
malignant pleural mesothelioma. Am J Pathol. 2011; 178: 
1033-1042.
22. Blanquart C, Francois M, Charrier C, Bertrand P, Gregoire 
M. Pharmacological characterization of histone deacetylase 
inhibitor and tumor cell-growth inhibition properties of new 
benzofuranone compounds. Curr Cancer Drug Targets. 
2011; 11: 919-928.
23. Minarini A, Milelli A, Fimognari C, Simoni E, Turrini E, 
Tumiatti V. Exploring the effects of isothiocyanates on 
chemotherapeutic drugs. Expert Opin Drug Metab Toxicol. 
2014; 10: 25-38.
24. Martins NM, Santos NA, Curti C, Bianchi ML, Santos 
AC. Cisplatin induces mitochondrial oxidative stress with 
resultant energetic metabolism impairment, membrane 
rigidification and apoptosis in rat liver. J Appl Toxicol. 
2008; 28: 337-344.
25. Rabik CA, Dolan ME. Molecular mechanisms of resistance 
and toxicity associated with platinating agents. Cancer Treat 
Rev. 2007; 33: 9-23.
26. Antosiewicz J, Ziolkowski W, Kar S, Powolny AA, Singh 
SV. Role of reactive oxygen intermediates in cellular 
responses to dietary cancer chemopreventive agents. Planta 
Med. 2008; 74: 1570-1579.
27. Sharma A, Singh K, Almasan A. Histone H2AX 
phosphorylation: a marker for DNA damage. Methods Mol 
Biol. 2012; 920: 613-626.
28. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang 
SM. Macrophages in tumor microenvironments and the 
progression of tumors. Clin Dev Immunol. 2012; 2012: 
948098.
29. Forman HJ, Torres M. Redox signaling in macrophages. 
Mol Aspects Med. 2001; 22: 189-216.
30. Xu K, Thornalley PJ. Studies on the mechanism of the 
inhibition of human leukaemia cell growth by dietary 
isothiocyanates and their cysteine adducts in vitro. Biochem 
Pharmacol. 2000; 60: 221-231.
31. Xu K, Thornalley PJ. Signal transduction activated by the 
cancer chemopreventive isothiocyanates: cleavage of BID 
protein, tyrosine phosphorylation and activation of JNK. Br 
J Cancer. 2001; 84: 670-673.
32. Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ, 
Young CY. Phenethyl isothiocyanate inhibits STAT3 
activation in prostate cancer cells. Mol Nutr Food Res. 
2009; 53: 878-886.
33. Lee JW, Cho MK. Phenethyl isothiocyanate induced 
apoptosis via down regulation of Bcl-2/XIAP and triggering 
of the mitochondrial pathway in MCF-7 cells. Arch Pharm 
Res. 2008; 31: 1604-1612.
34. Kang L, Wang ZY. Breast cancer cell growth inhibition by 
phenethyl isothiocyanate is associated with down-regulation 
of oestrogen receptor-alpha36. J Cell Mol Med. 2010; 14: 
1485-1493.
35. Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, Kong 
AN. Anti-NF-kappaB and anti-inflammatory activities of 
synthetic isothiocyanates: effect of chemical structures and 
cellular signaling. Chem Biol Interact. 2009; 179: 202-211.
36. Wu WJ, Zhang Y, Zeng ZL, Li XB, Hu KS, Luo HY, 
Yang J, Huang P, Xu RH. beta-phenylethyl isothiocyanate 
reverses platinum resistance by a GSH-dependent 
mechanism in cancer cells with epithelial-mesenchymal 
transition phenotype. Biochem Pharmacol. 2013; 85: 486-
496.
37. Wang X, Govind S, Sajankila SP, Mi L, Roy R, Chung FL. 
Phenethyl isothiocyanate sensitizes human cervical cancer 
cells to apoptosis induced by cisplatin. Mol Nutr Food Res. 
2011; 55: 1572-1581.
38. Di Pasqua AJ, Hong C, Wu MY, McCracken E, Wang X, 
Mi L, Chung FL. Sensitization of non-small cell lung cancer 
cells to cisplatin by naturally occurring isothiocyanates. 
Chem Res Toxicol. 2010; 23: 1307-1309.
39. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta 
C, Mutti L, Gaudino G. Taurolidine and oxidative stress: a 
rationale for local treatment of mesothelioma. Eur Respir J. 
2009; 34: 1399-1407.
40. Shi Y, Felley-Bosco E, Marti TM, Stahel RA. Differential 
effects of lovastatin on cisplatin responses in normal 
human mesothelial cells versus cancer cells: implication 
for therapy. PLoS One. 2012; 7: e45354.
41. Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen 
CB, Santoni-Rugiu E. Low ERCC1 expression in malignant 
pleural mesotheliomas treated with cisplatin and vinorelbine 
predicts prolonged progression-free survival. J Thorac 
Oncol. 2012; 7: 249-256.
42. Storr SJ, Woolston CM, Martin SG. Base excision repair, 
the redox environment and therapeutic implications. Curr 
Mol Pharmacol. 2012; 5: 88-101.
43. Kinnula VL, Everitt JI, Mangum JB, Chang LY, Crapo 
JD. Antioxidant defense mechanisms in cultured pleural 
mesothelial cells. Am J Respir Cell Mol Biol. 1992; 7: 95-
103.
44. Lee Y, Kim YJ, Choi YJ, Lee JW, Lee S, Chung 
HW. Enhancement of cisplatin cytotoxicity by benzyl 
isothiocyanate in HL-60 cells. Food Chem Toxicol. 2012; 
50: 2397-2406.
45. Fridman WH, Sautes-Fridman C. [The tumoral 
microenvironment: feeding resources, battle field and 
therapeutic target in cancer]. Med Sci (Paris). 2014; 30: 
359-365.
